In the field of colon cancer treatments beyond surgery and radiation, a key question has gained the protrusion in recent years: the volume DNA repair system is defective of the volume repair system, making it “microdimetic unstable”? About 15 to 20 percent of all tumors have this feature, making potential candidates for successful immunotherapy. So-called immuno-controlle inhibitors are often used in these cases to neutralize the “protective shield” of the tumor, which deceives the immune system to perceive it as harmless tissue. Once this cheating is raised, the T-cells of the body can eliminate the tumor.
However, many colon cancers remain resistant to immunotherapy and even chemotherapy and radiation. The cause lies in the tumor environment, explains Professor Florian Greten, a cancer researcher at Georg-Speyer-Haus and the University of Goethe Frankfurt and the TRR 417 representatives: “Tumors do not grow as foreign bodies within the intestinal tissue. micro -organisms – the microbicide.
The new TRR 417 Cooperation Research Center “Cellular Communication in the Cancer Cancer Mattress The aim is to continue researching this tumor of the microerebral. Greten explains: “We rely on the experience we have gained since 2016 through our collaboration with the DFG 2438 research unit on this subject. In this project we have not only concentrated numerous scientific ideas, but also developed common standards, models and technologies.” It is based on this foundation that researchers will now develop new therapeutic strategies. “We want to determine how to deliberately modify the tumor microenvironment and take advantage of it to reinforce therapies and make them accessible to immunotherapy – especially for those colon cancers that today respond to existing treatments.”
The success of the Trr 417 is particularly enjoyable because it shows how Professor Greten and his colleagues have strategically gathered the leading oncology experts from the leading institutions – German Cancer Aid, the German Cancer Consortium for Cancer Research for Cancer Cancer for Cancer Cancer for Cancer Cancer. Their approach to rapidly transferring basic research to clinical practice is a model for the profile area of ”Science for Health” at Goethe University. I look forward to the rich scientific production and the next generation of scientists clinics that will emerge from this collaborative research center. ”
Professor Enrico Schleiff, President of Goethe University
DFG will fund the TRR 417 for a four -year initial period with about 17.7 million euros. Funding can be renewed twice for an additional four -year periods.
Source:
